|
New kit offers researchers and development teams a meaningful advance in expression speed and output
BOSTON, May 13, 2026 /PRNewswire/ -- GenScript Biotech Corporation announced the launch of TurboCHO™ Protein Expression Kit, a next-generation antibody expression reagent designed to set a new benchmark for speed, performance, output and ease-of-use. One of the company's largest global product launches to date, this kit targets the fast-growing expression reagent market, driven by high-throughput and AI-enabled research.
Producing research-grade antibodies and proteins is a foundational step in drug discovery and biologics development. The new kit brings GenScript's proven protein-expression technology directly to the bench in a ready-to-use format, enabling labs of any size to generate high‑quality protein in as little as five business days. As a result, researchers can access reliable data sooner and make earlier, more confident decisions.
"TurboCHO™ Protein Expression Kit delivers outstanding performance and unmatched value, putting powerful innovation within reach of every lab working to advance science," said GenScript's Rotating CEO Sherry Shao. "By providing a launchpad to market, this kit helps bring new medicines to patients' faster, when time matters most."
The product debuted yesterday at the opening of the PEGS Summit in Boston, but attendees will have opportunities throughout the week to learn more and engage with the GenScript team. The Protein Expression Kit is available in two configurations:
- Pro: Delivers high-yield protein expression in as little as 5 business days, designed for easy integration into existing workflows.
- Prime (Licensed): Enhanced performance for teams seeking maximum speed, with results as early as Day 3 and even higher yields.
Early Feedback Supports Real-World Impact
Early adopters in the beta program have reported performance that is "best in class" for speed and value, demonstrating its real-world impact.
_________________________________________________________________________________
Performance Snapshot: How the Kit Compares
- Redefines expression speed, providing Day 5 yields (or Day 3 for Prime) comparable to competitor Day 10 results, substantially shortening timelines and accelerating decision-making
- Delivers higher yields with lower reagent input, improving overall cost efficiency and throughput
- Produces up to three-fold higher yield(or 5-fold for Prime) after Protein A purification versus other market solutions
- Features a proprietary high‑performing cell line and optimized transfection system
_________________________________________________________________________________
For drug developers and research teams managing increasingly compressed discovery timelines, this performance translates into faster candidate selection, reduced time-to-data, and the capacity to validate more candidates as they move into experimental testing.
The launch represents the first phase of a broader innovation roadmap designed to drive continued industry leadership, with planned advances spanning next‑generation CHO cell line enhancements, improved transfection systems, and scalable, automation‑ready formats.
"By delivering higher-quality antibody expression with dramatically faster time-to-data, we are eliminating a critical bottleneck in drug discovery," said Ray Chen, President of GenScript Life Science Group. "Designed for today's complex molecules, this kit ensures reproducibility and seamless screen-to-scale translation, while enabling more designs to be tested at lower cost. For research teams working under aggressive discovery timelines, the real question isn't whether to adopt this solution. It's how quickly they choose to leverage it to redefine what's possible."
TurboCHO™ Protein Expression Kit is available immediately through GenScript's direct sales channels and authorized distributors. To support early adoption, GenScript is offering introductory pricing for a limited time, along with technical support for onboarding and workflow optimization. Inventory is in place to support both domestic and international demand. For more information or pricing, visit the GenScript website.
About GenScript
Founded in 2002 in New Jersey, GenScript Biotech Corporation accelerates innovation in biotech and healthcare by providing researchers and companies with the building blocks needed to develop groundbreaking treatments and products. As a cornerstone of the global life science ecosystem, GenScript actively collaborates with a diverse network of partners—from academic institutions to industry leaders—to co-create cutting-edge solutions that redefine service excellence. Guided by its mission to Make People and Nature Healthier Through Biotechnology, GenScript has become a trusted global partner with a team of 6,100+ employees, supporting over 200,000 customers across 100+ countries and regions, including the world's Top 20 pharma companies. For more information: www.genscript.com
Media Contacts:
Kate Grusich
Senior Corporate Communications Manager
Katherina.Grusich@genscript.com
New kit offers researchers and development teams a meaningful advance in expression speed and output
BOSTON, May 13, 2026 /PRNewswire/ -- GenScript Biotech Corporation announced the launch of TurboCHO™ Protein Expression Kit, a next-generation antibody expression reagent designed to set a new benchmark for speed, performance, output and ease-of-use. One of the company's largest global product launches to date, this kit targets the fast-growing expression reagent market, driven by high-throughput and AI-enabled research.
Producing research-grade antibodies and proteins is a foundational step in drug discovery and biologics development. The new kit brings GenScript's proven protein-expression technology directly to the bench in a ready-to-use format, enabling labs of any size to generate high‑quality protein in as little as five business days. As a result, researchers can access reliable data sooner and make earlier, more confident decisions.
"TurboCHO™ Protein Expression Kit delivers outstanding performance and unmatched value, putting powerful innovation within reach of every lab working to advance science," said GenScript's Rotating CEO Sherry Shao. "By providing a launchpad to market, this kit helps bring new medicines to patients' faster, when time matters most."
The product debuted yesterday at the opening of the PEGS Summit in Boston, but attendees will have opportunities throughout the week to learn more and engage with the GenScript team. The Protein Expression Kit is available in two configurations:
- Pro: Delivers high-yield protein expression in as little as 5 business days, designed for easy integration into existing workflows.
- Prime (Licensed): Enhanced performance for teams seeking maximum speed, with results as early as Day 3 and even higher yields.
Early Feedback Supports Real-World Impact
Early adopters in the beta program have reported performance that is "best in class" for speed and value, demonstrating its real-world impact.
_________________________________________________________________________________
Performance Snapshot: How the Kit Compares
- Redefines expression speed, providing Day 5 yields (or Day 3 for Prime) comparable to competitor Day 10 results, substantially shortening timelines and accelerating decision-making
- Delivers higher yields with lower reagent input, improving overall cost efficiency and throughput
- Produces up to three-fold higher yield(or 5-fold for Prime) after Protein A purification versus other market solutions
- Features a proprietary high‑performing cell line and optimized transfection system
_________________________________________________________________________________
For drug developers and research teams managing increasingly compressed discovery timelines, this performance translates into faster candidate selection, reduced time-to-data, and the capacity to validate more candidates as they move into experimental testing.
The launch represents the first phase of a broader innovation roadmap designed to drive continued industry leadership, with planned advances spanning next‑generation CHO cell line enhancements, improved transfection systems, and scalable, automation‑ready formats.
"By delivering higher-quality antibody expression with dramatically faster time-to-data, we are eliminating a critical bottleneck in drug discovery," said Ray Chen, President of GenScript Life Science Group. "Designed for today's complex molecules, this kit ensures reproducibility and seamless screen-to-scale translation, while enabling more designs to be tested at lower cost. For research teams working under aggressive discovery timelines, the real question isn't whether to adopt this solution. It's how quickly they choose to leverage it to redefine what's possible."
TurboCHO™ Protein Expression Kit is available immediately through GenScript's direct sales channels and authorized distributors. To support early adoption, GenScript is offering introductory pricing for a limited time, along with technical support for onboarding and workflow optimization. Inventory is in place to support both domestic and international demand. For more information or pricing, visit the GenScript website.
About GenScript
Founded in 2002 in New Jersey, GenScript Biotech Corporation accelerates innovation in biotech and healthcare by providing researchers and companies with the building blocks needed to develop groundbreaking treatments and products. As a cornerstone of the global life science ecosystem, GenScript actively collaborates with a diverse network of partners—from academic institutions to industry leaders—to co-create cutting-edge solutions that redefine service excellence. Guided by its mission to Make People and Nature Healthier Through Biotechnology, GenScript has become a trusted global partner with a team of 6,100+ employees, supporting over 200,000 customers across 100+ countries and regions, including the world's Top 20 pharma companies. For more information: www.genscript.com
Media Contacts:
Kate Grusich
Senior Corporate Communications Manager
Katherina.Grusich@genscript.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
GenScript Launches TurboCHO™ Protein Expression Kit, Delivering the Fastest Path to Antibodies in its Class
GenScript Launches TurboCHO™ Protein Expression Kit, Delivering the Fastest Path to Antibodies in its Class
Institutional-grade Silver is now accessible on Sui, expanding XAGm's use in on-chain financial systems
SINGAPORE, May 12, 2026 /PRNewswire/ -- Matrixdock today announced the expansion of its tokenized silver product, XAGm, to Sui, extending its on-chain commodities offering beyond Ethereum. The move enables institutional-grade silver to be actively used across trading, lending, and collateralized applications, reflecting a broader shift in on-chain finance from asset issuance toward real financial execution.
A new phase of on-chain finance is emerging. Real-world assets (RWAs) are no longer defined by their ability to be tokenized, but by their ability to function—moving, interacting, and serving as collateral within programmable financial systems.
Sui is a next-generation Layer 1 blockchain built for scalable finance and global payments. It makes assets, permissions, and user data programmable and ownable, thereby serving as the ideal platform for broader utilization of RWAs. Matrixdock complements this foundation by serving the reserve layer for on-chain finance—bringing institutional-grade assets on-chain with transparency, asset integrity, and real utility.
Today, this shared vision advances as Matrixdock brings Matrixdock Silver (XAGm) to Sui, extending its collaboration beyond tokenized gold into a greater on-chain commodities strategy.
XAGm is a fully allocated, institutional-grade tokenized silver asset backed by London Bullion Market Association (LBMA)-accredited silver. Natively issued on Sui, each token is directly linked to underlying vaulted bullion, supported by independent verification and professional custody. By bringing silver on-chain, XAGm transforms a traditionally static asset into one that can move seamlessly across trading, lending, and collateralized financial applications.
Despite growing demand for silver exposure, institutional-grade on-chain silver remains scarce. Existing products often lack verifiable reserves, sufficient liquidity, or the ability to integrate into financial applications.
The Sui Foundation has indicated plans to allocate a portion of its treasury into XAGm, signaling alignment and confidence in tokenized silver as a reserve-grade asset within on-chain financial infrastructure.
From Issuance to Execution
Ethereum established the foundation for tokenized assets–prioritizing transparency, composability, and market access. Within this environment, XAGm demonstrated that institutional-grade commodities can exist on-chain with verifiable backing.
Sui represents the next phase.
With its horizontally scalable architecture, parallel execution engine, and sub-second finality, Sui enables assets to operate within high-performance financial systems — where they are not only issued, but actively used. This marks a broader transition in blockchain design: from passive issuance layers to execution environments capable of supporting real-time financial activity at scale.
This transition is driven by two forces: growing demand for reliable collateral in DeFi, and the emergence of high-performance blockchains capable of supporting real-time financial activity.
"Tokenized assets are at the forefront of this new era of global finance, where assets move at the speed of messages, and Sui is uniquely positioned to underpin and power all the necessary components at scale," said Adeniyi Abiodun, Co-Founder and Chief Product Officer at Mysten Labs, the original contributors to Sui. "We're pleased to work with Matrixdock to expand into its tokenized silver product, XAGm."
Silver as a Functional Asset
Unlike gold, which primarily serves as a store of value, silver presents a fundamentally different profile. Its industrial demand and higher volatility make it structurally suited for active financial use.
"Gold proved that real-world assets can exist on-chain. Silver is where they start to function," said Eva Meng, Head of Matrixdock.
"Following gold, silver represents the next evolution of on-chain commodities—where liquidity, utility, and programmability converge. With XAGm, we are enabling silver to function as institutional-grade collateral across decentralized markets, without compromising on transparency or asset integrity. There are very few spot silver assets today that meet the requirements of DeFi at an institutional standard, and this is the gap XAGm is designed to fill. Sui's architecture allows us to deliver this at scale."
XAGm introduces Matrixdock's Fungible Reserve Standard (FRS), an issuance framework that preserves fungibility while reconciling token supply with underlying reserves as real-world carry is recognized over time. This ensures that token supply remains consistently aligned with underlying assets without introducing hidden risk or compromising composability across DeFi.
As on-chain derivatives markets evolve–particularly with rising demand for silver perpetuals–the need for underlying spot assets that can support trading, hedging, and collateralization becomes essential. Assets such as XAGm are no longer optional–they become foundational infrastructure.
Infrastructure Designed to Scale
Sui's parallel execution model, sub-second finality, and horizontally scalable infrastructure enable instantaneous, cost-efficient transactions — critical for high-frequency financial use cases and collateral movement. Its security and reliability provide the foundation for global-scale adoption of tokenized real-world assets.
This shift — from issuance to execution, from representation to utility — reflects a structural redefinition of how real-world assets participate in financial systems. Together, Matrixdock and Sui are advancing a shared vision: reserve-grade assets that are transparent, verifiable, and natively integrated into internet capital markets.
About Sui
Sui, where money moves as freely as messages, is a next-generation Layer 1 blockchain built for scalable finance and global payments. Founded by the core team behind Meta's stablecoin initiative and powered by an object-centric model, Sui makes assets, permissions, and user data programmable and ownable. Sui's primitives offer builders everything they need to create high-performance payments and financial applications, including instant agentic payments. Learn more at sui.io.
Contact: media@sui.io
About Matrixdock
Matrixdock is Asia's leading real-world asset (RWA) tokenization platform, focused on bringing institutional-grade assets onto on-chain capital markets through fully allocated, transparent and verifiable structures.
Its products include Matrixdock Gold (XAUm) and Silver (XAGm), each backed 1:1 by LBMA-accredited bullion with token-to-bar allocation, and STBT, a tokenized short-term U.S. Treasury product designed for on-chain liquidity and collateral use. All assets are held in professional custody, independently verified, with full transparency and integration across leading blockchain ecosystems.
Matrixdock also partners with sovereign and institutional initiatives, including the architecture and technical development of TER, the world's first sovereign-backed gold token for Gelephu Mindfulness City (GMC) in the Kingdom of Bhutan.
Matrixdock is building the reserve layer for on-chain capital markets.
Matrixdock official website: https://www.matrixdock.com/
Contact: support@matrixdock.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Matrixdock Expands Tokenized Silver (XAGm) to Sui, Enabling Institutional-Grade Access for On-Chain Finance
